Axsome Therapeutics Inc (NASDAQ:AXSM)
| 68.01 Delayed Data As of Dec 01 |  +0.56 / +0.83%Today’s Change | 53.71 Today|||52-Week Range 91.29 | -11.82% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $3.2B |
Company Description
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Contact Information
Axsome Therapeutics, Inc. One World Trade Center New York New York 10007 |
Employees
Shareholders
| Other institutional | 55.69% |
| Mutual fund holders | 23.88% |
| Individual stakeholders | 19.31% |
Top Executives
| Herriott Tabuteau | Chairman, President & Chief Executive Officer |
| Mark L. Jacobson | Chief Operating Officer |
| Nick Pizzie | Chief Financial Officer |
| Lori Englebert | Executive VP-Commercial & Business Development |
| Kevin Laliberte | Executive Vice President-Product Strategy |
